JP2008505143A - Ｇ２５０発現腫瘍の改善されたアジュバント療法 - Google Patents

Ｇ２５０発現腫瘍の改善されたアジュバント療法 Download PDF

Info

Publication number
JP2008505143A
JP2008505143A JP2007519679A JP2007519679A JP2008505143A JP 2008505143 A JP2008505143 A JP 2008505143A JP 2007519679 A JP2007519679 A JP 2007519679A JP 2007519679 A JP2007519679 A JP 2007519679A JP 2008505143 A JP2008505143 A JP 2008505143A
Authority
JP
Japan
Prior art keywords
antibody
antigen
patients
weeks
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505143A5 (https=
Inventor
ヴィルヘルム オラフ
ヴァールナー スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Publication of JP2008505143A publication Critical patent/JP2008505143A/ja
Publication of JP2008505143A5 publication Critical patent/JP2008505143A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007519679A 2004-07-02 2005-06-29 Ｇ２５０発現腫瘍の改善されたアジュバント療法 Pending JP2008505143A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (2)

Publication Number Publication Date
JP2008505143A true JP2008505143A (ja) 2008-02-21
JP2008505143A5 JP2008505143A5 (https=) 2008-05-29

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519679A Pending JP2008505143A (ja) 2004-07-02 2005-06-29 Ｇ２５０発現腫瘍の改善されたアジュバント療法

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034182A1 (ja) 2009-09-18 2011-03-24 三菱化学株式会社 肝細胞癌マーカー

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2901531C (en) 2013-02-22 2022-03-29 Wilex Ag Caix stratification based cancer treatment
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (en) * 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (en) * 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN6011019265; Ｌａｕ　ＷＫ　ｅｔ　ａｌ．: 'Ｐｒｏｇｎｏｓｔｉｃ　ｆｅａｔｕｒｅｓ　ｏｆ　ｐａｔｈｏｌｏｇｉｃ　ｓｔａｇｅ　Ｔ１　ｒｅｎａｌ　ｃｅｌｌ　ｃａｒｃｉｎｏｍａ　ａｆｔｅｒ　ｒａｄｉｃａｌ　ｎｅｐｈｒｅｃｔｏｍｙ．' Ｕｒｏｌｏｇｙ． Ｖｏｌ．５９　ｎｏ．４, 200204, ｐｐ．５３２-５３７ *
JPN6011019275; Ｐｈｉｌｌｉｐｓ　ＣＫ　ａｎｄ　Ｔａｎｅｊａ　ＳＳ．: 'Ｔｈｅ　ｒｏｌｅ　ｏｆ　ｌｙｍｐｈａｄｅｎｅｃｔｏｍｙ　ｉｎ　ｔｈｅ　ｓｕｒｇｉｃａｌ　ｍａｎａｇｅｍｅｎｔ　ｏｆ　ｒｅｎａｌ　ｃｅｌｌ　ｃａｒｃｉｎｏｍａ．' Ｕｒｏｌ　Ｏｎｃｏｌ Ｖｏｌ．２２　ｎｏ．３, 200406, ｐｐ．２１４-２２３ *
JPN6014019843; ＡＪＰ Ｖｏｌ．１４５，Ｎｏ．３, 1994, ｐ．５９８-６０９
JPN6014019844; ＰＭＩＤ：９１９１０１０ , 1997
JPN6014019845; ＰＭＩＤ：１１６９０７１１ , 2001
JPN6014019848; Ｅｕｒ．　Ｒｅｓｐｉｒ．　Ｊ． Ｖｏｌ．１４, 1999, ｐ．８０６-８１１
JPN6014019850; ＡＪＰ Ｖｏｌ．１５３，Ｎｏ．１, 1998, ｐ．２７９-２８５
JPN6014019857; ＢＪＣ Ｖｏｌ．９０, 20040302, ｐ．９８５-９９０
JPN6014020191; Ｌａｂｅｌ　Ｉｎｆｏｒｍａｔｉｏｎ　ｆｏｒ　ＥＲＢＩＴＵＸ , 20040212
JPN6014020192; Ｌａｂｅｌ　ｉｎｆｏｒｍａｔｉｏｎ　ｆｏｒ　ＨＥＲＣＥＰＴＩＮ , 19980925
JPN6014020402; Ｉｎｔ．　Ｊ．　Ｍｏｌ．　Ｓｃｉ． Ｖｏｌ．１４，Ｎｏ．６, 2013, ｐ．１１４０２-１１４２３
JPN6014021245; Ｉｎｔ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．５３, 1993, ｐ．７５１-７５８

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034182A1 (ja) 2009-09-18 2011-03-24 三菱化学株式会社 肝細胞癌マーカー

Also Published As

Publication number Publication date
WO2006002889A3 (en) 2006-10-05
EP2497497A1 (en) 2012-09-12
RU2371198C2 (ru) 2009-10-27
RU2009122344A (ru) 2010-12-20
DK2497497T3 (en) 2017-08-14
US7691375B2 (en) 2010-04-06
AU2005259481B2 (en) 2010-04-22
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
US20070207157A1 (en) 2007-09-06
CN101052416B (zh) 2013-07-10
KR101205289B1 (ko) 2012-11-27
ES2641089T3 (es) 2017-11-07
CN101052416A (zh) 2007-10-10
RU2519340C2 (ru) 2014-06-10
WO2006002889A2 (en) 2006-01-12
AU2005259481A1 (en) 2006-01-12
RU2007104040A (ru) 2008-08-10
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
KR20070036085A (ko) 2007-04-02
EP1763367A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
Scott et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake
US20190270812A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
JP2019532999A (ja) Ｈｅｒ２陽性乳がんの治療
CN115066260A (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
Henry et al. ERK inhibition improves anti–PD-L1 immune checkpoint blockade in preclinical pancreatic ductal adenocarcinoma
JP7553439B2 (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
CN113244386A (zh) 抗pd-1抗体在治疗肿瘤中的用途
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
CN115364209A (zh) 抗pd-1抗体联合化疗治疗食管癌的用途
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
Koynov et al. Aflibercept Plus FOLFIRI for Colorectal Cancer in Bulgarian Clinical Practice
JP2024527049A (ja) がんを治療するための方法及び組成物
ZA200607849B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US20190211102A1 (en) Methods and combination therapy to treat cancer
HK40097418A (zh) Her2阳性乳腺癌的辅助治疗
Van Ooteghem et al. Members of the jury
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
HK40015029B (zh) Her2阳性乳腺癌的辅助治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080408

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120305

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140116